Ryoncil Profits Underpinning Substantial Growth Pipeline
Filed with ASX · · 7 pages · English
In the deck
Earlier from Mesoblast
- Corporate Presentation and Half Year Financial Results
- Half Year Report and Accounts (including Appendix 4D)
- High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
- Quarterly Activities/Appendix 4C Cash Flow Report
- Ryoncil® Net Revenues Increase for the Quarter to US$30M
Later from Mesoblast
- Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
- Mesoblast to Host R&D Day on April 8, 2026
- Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
- Ryoncil Net Revenue for the Quarter Increases to US$30.3M
- Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast